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Summary: Three groups of patients receiving oral anticoagulation treatment were evaluated. The groups
consisted of patients with mechanical heart valve prosthesis (n = 60), patients after coronary bypass graft
surgery (n = 60) and patients using oral anticoagulation after deep venous thrombosis or pulmonary embolism
(n = 60).
The patient groups were subdivided into three groups of 20 patients, each group receiving different levels of
oral anticoagulation as indicated by the international normalized ratio (INR). Prothrombin fragment 1+2 ,
thrombin-antithrombin III complexes and fibrin monomers were determined as coagulation activation makers.
The prothrombin fragments 1 + 2 were INR dependent in all groups whereas the thrombin-antithrombin III
values were only INR dependent in the group of patients with mechanical heart valve prosthesis. For fibrin
monomers no correlation with the INR levels could be found.
These results indicate that prothrombin fragment 1 + 2 is the only laboratory quantity of the three, which
provides a suitable index of low thrombin activity during anticoagulation therapy.
Introduction . .
 r u uthe risk of major haemorrhage (10). From the labo-
There is wide acceptance that oral anticoagulants are ratory point of view, the final aim of oral anticoa-
effective in the primary and secondary prevention of gulation is the reduction of thrombin generation to
thromboembolic complications after deep venous such a level that fibrin can no longer be formed in
thrombosis (1), in patients with mechanical or bio- harmful quantities.
logical heart valve prosthesis (2, 3), after myocardial
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. r .. ,Λ\ · ^ *· r * ι /c\ Λ Λ Several tests for the activation extent of the haemo-infarction (4), in the prevention of stroke (5) and after . ., , , , ,
' j. /r\ -π. · * ·* c ι static system are now available, such as the measure-
major orthopaedic surgery (6). The intensity of oral ' , . ., . , ' . , , .
 TTT
- f i , r ,· ment of nbnnopeptide A, thrombin-antithrombin III
anticoagulation however has been matter of discus- . .... * . „ , « .
« , . ,„ ox TT· t · · · complex (II), fibrin monomer as well as prothrombin
sion for a long time (7, 8). High-intensity anticoagu- r \ ' _u ^u .ι · /Txir» ο Λ /ι m u *u · i r · fragment 1 + 2. The levels of both fibnnopeptide Alation (INR 3.0 — 4.0) enhances the risk of minor or . , . . . , , . ^ /Λ\ ι.
,\ ,. t - - ^ r ι · · (12, 13) and prothrombin fragment 1 + 2 (14) have
major bleeding complications. Moderate-intensity a n - ^ ' « , j t j i ·
, . XT-KTT,Γ ^ Λ ^ /-χ ι ι been shown to be dependent on the degree of anti-ticoagulation (INR 2.0 — 2.5), however, may be .
11 rr *· - j- * j · i r · ι * · ι coagulation,equally effective, as indicated in several clinical trials
in patients with bioprosthesis of the heart valve (2) A scheme of the relevant part of the coagulation and
or after deep venous thrombosis (9), and might lower fibrinolysis cascade is shown in figure 1.
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Fig. 1. Scheme of the relevant part of the coagulation and fibrinolysis cascade.
The aim of this study was to establish the extent of
prothrombin activation and its effect on thrombin
activity in several patient groups receiving different
degrees of oral anticoagulation treatment, and to
compare the measured quantities (i. e. thrombin-an-
tithrombin III, fibrin monomer, prothrombin frag-
ment 1 -f 2) with regard to their usefulness as an
index of thrombin activity during oral anticoagula-
tion.
Materials and Methods
Methods
The ELISA test kit Enzygnost® thrombin-antithrombin III of
Behring Corp. (Marburg, Germany) was used for thrombin-
antithrombin III measurements. Prothrombin fragment 1 + 2
was determined with the Enzygnost® Fl + 2 of Behring Corp.
(Marburg, Germany). Fibrin monomers were measured with
the chromogenic Coa set test of Kabi Vitrum Diagnostica
(M lndal, Sweden). Prothrombin times were assessed with the
Chromoquick® reagent of Behring Corp. (Marburg, Germany)
on a Cobas Bio (Hoffmann-La Roche, Grenzach-Wyhlen,
Switzerland) and were reported as INR-values.
Patients
Three groups of patients were evaluated. All patients were
monitored routinely for the efficiency of oral anticoagulation
treatment.
Group 1 consisted of 60 patients with (mechanical) heart valve
prosthesis.
Group 2 contained 60 patients after coronary artery bypass
graft surgery.
Group 3 was composed of 60 patients using oral anticoagulation
after deep venous thrombosis or pulmonary embolism.
Group 1 and 3 were subdivided into anticoagulation levels INR
3.6-4.8, INR 2.5-3.5 and INR 2.1-2.4. Group 2 was sub-
divided into INR 2.9-4.8, INR 2.1-2.8 and INR 1.8-2.0.
The levels of each group were determined according to the
recommendations for optimal anticoagulation of the Federation
of Dutch Thrombosis Centers (15). All patients were under
stable oral anticoagulation and were attributed to one of the
categories on the basis of their actual INR values. The reference
values were obtained from 50 age and sex matched healthy
individuals.
Samples
Blood was collected between 9 and 11 a. m. in trisodium citrate
(0.11 mol/l)-containing plastic tubes (9:1 by vol.). After cen-
trifugation (1600g, 20 min, room temperature) the plasma was
collected, analysed for the prothrombin time and after that
immediately deep frozen at -70 °C until batch analysis of the
specimens for the other analytes was performed. Before analysis
they were thawed with tap water for 5 min just before use.
Results
In table 1 the medians and interquartile ranges of the
investigated quantities are given for the group of
healthy individuals.
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Tab. 1. Medians, interquartile ranges and reference ranges for the different parameters in healthy individuals.
Quantity Group of healthy individuals (N = 50)
Median Interquartile range Reference range
Prothrombin fragment 1 + 2 (nmol/1)
Thrombin-anti thrombin III ^g/l)
Fibrin monomers (nmol/1)
0.66
2.4
10.5
0.26
1.4
2.0
0.44- 1.11
1.0- 4.1
8.4-13.2
In table 2 the Spearman rank coefficients of correla-
tion are given between INR and prothrombin frag-
ment 1 + 2, thrombin-antithrombin III and fibrin
monomers in the different patient groups. Only pro-
thrombin fragment 1 + 2 concentrations showed sig-
nificant correlations with INR in all patient groups.
A thrombin-antithrombin III correlation with INR
only was obtained in the group with mechanical heart
valve prosthesis (r = -0.36, p = 0.004).
Table 3 shows the results of the comparison of the
different quantities in the group of patients with me-
chanical heart valve prosthesis according to their INR
category:
a significant increase was found for prothrombin frag-
ment 1+2 ; thrombin-antithrombin III values were
significantly different between categories INR3 and
INRl5 and between INR3 and INR2; fibrin monomers
showed a significant difference only between INR3
and INR2.
The comparison of the investigated quantities in the
group of patients with coronary artery bypass grafts
in the different INR groups is given in table 4; pro-
thrombin fragment 1 + 2 was the only variable with
significant alterations: INR2 vs INR! p < 0.005, INR3
vs INRi p < 0.001. Table 5 contains the results of the
comparison of the deep venous thrombosis and pul-
monary embolism patient groups; significant pro-
thrombin fragment 1 + 2 differences were obtained
between INR2 and INRj (p < 0.03), INR3 and INR2
(p < 0.01), and between INR3 and INR! (p < 0.001).
Discussion
The intensity of oral anticoagulation has long been
matter of discussion, and the problem always has
been approached from a clinical standpoint. It is
common opinion that the ultimate goal of treatment
with oral anticoagulation is the prevention of throm-
bin formation or the reduction thereof to a level where
Tab. 2. Spearman rank correlation (p-values) between INR levels and prothrombin fragment 1+2, thrombin-antithrombin III
and fibrin monomer.
Spearman rank correlation (p-values) between INR and
Prothrombin fragment 1 + 2 Thrombin-antithrombin III Fibrin monomer
Group 1 (n
Group 2 (n
Group 3 (n
= 60)
= 60)
= 60)
-0.56
-0.47
-0.50
(< 0.0001)
( 0.0002)
(< 0.0001)
-0.36
0.09
-0.11
(0.004)
(0.48)
(0.36)
-0.06
0.09
-0.15
(0.65)
(0.47)
(0.23)
Group 1 = patients with mechanical heart valve prosthesis
Group 2 = patients with coronary artery bypass grafts
Group 3 = patients after deep venous thrombosis or pulmonary embolism
Tab. 3. Comparison of the medians and interquartile ranges (IR) of the investigated quantities in the group of patients with
mechanical heart valve prosthesis according to the INR categories. The significances were calculated with the Mann-
Whitney-Wilcoxon test. Each INR subgroup consisted of 20 patients.
Quantity
Prothrombin fragment 1 + 2 (nmol/1)
Thrombin-antithrombin III (\ig/\)
Fibrin monomer (nmol/1)
INR1
(4.8 3.6)
Median
(IR)
0.12
(0.08)
1.5
(0.4)
16.8
(4.7)
INR2
(3.5-2.5)
Median
(IR)
0.15
(0.09)
1.6
(0.5)
14.4
(3.3)
INR3
(2.4-2.1)
Median
(IR)
0.25
(0.18)
2.0
(0.8)
17.6
(8.3)
Significances P-values
2 vs 1 3 vs 2
<0.03 < 0.0001
N.S. < 0.005
N.S. <0.02
3 v s l
< 0.001
< 0.005
N.S.
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Tab. 4. Comparison of the medians and interquartile ranges (IR) of the investigated quantities in the group of patients with
coronary artery bypass grafts according to the INR categories. The significances were calculated with the Mann-Whitney-
Wilcoxon test. Each INR subgroup consisted of 20 patients.
Quantity
Prothrombin fragment 1 + 2 (nmol/1)
Thrombin-antithrombin III (μ&/\)
Fibrin monomer (nmol/1)
INR1
(4.8 2.9)
Median
(IR)
0.20
(0.11)
1.7
(0.6)
19.1
(6.0)
INR2
(2.8-2.1)
Median
(IR)
0.27
(0.21)
1.9
(0.9)
17.8
(7.1)
INR3
(2.0-1.8)
Median
(IR)
0.32
(0.15)
1.7
(0.6)
17.3
(8.6)
Significances
2 v s l
<0.005
N.S.
N.S.
P-values
3vs2
N.S.
N.S.
N.S.
3 vs 1
< 0.001
N.S.
N.S.
Tab. 5. Comparison of the medians and interquartile ranges (IR) of the investigated quantities in the group of patients with
prophylactical treatment after deep venous thrombosis or pulmonary embolism according to the INR categories. The
significances were calculated with the Mann- Whitney- Wilcoxon test. Each INR subgroup consisted of 20 patients.
Quantity
Prothrombin fragment 1 + 2 (nmol/1)
Thrombin-antithrombin III ^g/l)
Fibrin monomer (nmol/1)
INR1
(4.8 3.6)
Median
(IR)
0.15
(0.06)
1.4
(0.3)
16.7
(9.2)
INR2
(3.5-2.5)
Median
(IR)
0.17
(0.07)
1.4
(0.3)
16.8
(8.1)
INR3
(2.4-2.1)
Median
(IR)
0.23
(0.16)
1.4
(0.6)
20.4
(5.3)
Significances
2 v s 2
<0.03
N.S.
N.S.
P-values
3 v s 2
<0.01
N.S.
<0.02
3vs 1
< 0.001
N.S.
N.S.
Tab. 6. Comparison of the medians and interquartile ranges (IR) of the investigated quantities in the group of patients with
prophylactical treatment after total hip or knee arthroplasty according to the INR categories. The significances were
calculated with the Mann- Whitney- Wilcoxon test. Each INR subgroup consisted of 20 patients.
Quantity
Prothrombin fragment 1 + 2 (nmol/1)
Thrombin-antithrombin III (μ§/1)
Fibrin monomer (nmol/1)
INR2
(3.5-2.5)
Median
(IR)
0.29
(0.13)
1.9
(0.4)
14.9
(4.8)
INR3
(2.4-2.1)
Median
(IR)
0.30
(0.13)
1.7
(0.9)
18.7
(2.9)
Significance
P-value
3 v s 2
N.S.
N.S.
N.S.
no or nearly no thrombin generation occurs. Up to
now the decreased activity of the coagulation system
during anticoagulation treatment has been determined
by measuring the prothrombin time as a global test
for the extrinsic coagulation pathway. We have now
used the relatively new assays for prothrombin frag-
ment 1 + 2 , thrombin-antithrombin III and fibrin
monomer and tested them for their usefulness as
markers of the effect of prothrombin activation and
of thrombin activity during oral anticoagulation. Cor-
relation studies between these coagulation activation
markers and the INR show that only prothrombin
fragment 1-1-2 decreases in all patient groups with
the increase of the INR. Thrombin-antithrombin III
decreased only in the group with mechanical heart
valve prosthesis. The fibrin monomer concentrations
showed no correlation in any patient group. Thus,
prothrombin fragment 1 + 2 seems to be suited for
the monitoring of the reduction of thrombin forma-
tion in patients under oral anticoagulation treatment.
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The results in the patient group with mechanical heart
valve prosthesis showed significantly decreased values
for prothrombin fragment 1 + 2 and low normal
thrombin-antithrombin III concentrations with in-
creasing INR values. The actual median concentra-
tions of prothrombin fragment 1 + 2 are located sig-
nificantly below those of the lower limit of the ref-
erence group. Thus, thrombin formation is depressed
to such a low level that from the laboratory point of
view a prolonged period in the lowest INR category
should not be a cause of concern in this patient group.
In the group of patients with coronary artery bypass
grafts, only prothrombin fragment 1 + 2 values
showed a decrease with increasing INR values. The
median values of the different anticoagulation intens-
ities are below the lower limit of the reference group
and are somewhat higher than those in the group of
patients with mechanical heart valve prosthesis. The
prothrombin fragment 1 + 2 levels are also low in
the group of patients receiving prophylactical treat-
ment with oral anticoagulants after deep venous
thrombosis and pulmonary embolism, and they also
decrease with increasing INR. The question is whether
the differences between the median values for pro-
thrombin fragment 1 + 2 in the different intensity
categories are an adequate index of the decrease of
the thrombin. Considering the effect of oral anticoa-
gulation in the three patient groups on the concentra-
tions of prothrombin fragment 1+2 , thrombin-an-
tithrombin III and fibrin monomer, it appears that
prothrombin fragment 1 + 2 is the most suitable for
the measurement of the effect of oral anticoagulation.
The test allows reliable measurements below the lower
limit of the reference range; this is of interest especially
in this study, which includes properly anticoagulated
patients. On the basis of the concentrations measured
for prothrombin fragment 1 + 2 it is clear that under
stable anticoagulation the resulting thrombin activity
is most depressed in the mechanical heart valve pros-
thesis and the deep venous thrombosis/pulmonary
embolism group, followed by the coronary artery
bypass graft group, but it is probably adequate in all
groups. The thrombin-antithrombin III concentra-
tions in the various patient groups and the different
intensity categories of oral anticoagulation are less
informative, although the median values are mostly
in the lower quartile of the reference range. The fibrin
monomer values are useless for the evaluation of the
reduced thrombin activity under oral anticoagulation.
The median values are even higher in the patient
groups than in the reference groups. The explanation
for this is unclear, but there might be some interfer-
ence in the test system. It is, however, also conceivable
that the enhancement of the tissue plasminogen acti-
vator concentrations in anticoagulated patients, as we
reported in a recent study (16), also plays a role.
Elevated tissue plasminogen activator concentrations
could produce additional plasmin in the test system,
which in turn would cause higher fibrin monomer
values than expected.
In conclusion, from the three markers of coagulation
activation used in this study, only the prothrombin
fragment 1 + 2 concentrations showed full inverse
parallelism with the INR levels. This has also been
reported recently by Mannucci (17). The median pro-
thrombin fragment 1 + 2 concentrations were
strongly reduced in all patient groups, indicating sat-
isfactory decrease of coagulation by oral anticoagu-
lation treatment. The measurement of prothrombin
fragment 1 + 2 seems to be appropriate in selected
cases as an additional value for adjusting and moni-
toring the efficacy of anticoagulant therapy. This is
important, because in general the question is whether
the high intensities of oral anticoagulation are nec-
essary for all indications as commonly recommended.
In several clinical studies less intense oral anticoagu-
lation (2, 3, 5, 9, 18 — 20) and other therapeutic regi-
mens (1, 21—26) have already been tested for the
different indications of oral anticoagulation. Meas-
urement of prothrombin fragment 1 + 2 might there-
fore be helpful in future clinical studies dealing with
the efficacy of oral anticoagulation.
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